statementSaid on 2026-11-11
CM383 has started Phase Ib clinical trials for mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease, and some brokerages regard it as a potential leading Aβ antibody in China; CM559 has also advanced to Phase I clinical trials.
A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.
CM383針對阿爾茨海默病源性輕度認知功能障礙和輕度阿爾茨海默病已開展Ib期臨床,被部分券商視為「潛在中國最領先的Aβ抗體」;CM559(N3pG Aβ抗體)亦已推進至I期臨床。